Aviña FJA, López BR, Toro CJL

Idioma: Español
Referencias bibliográficas: 23
Paginas: 104-108
Archivo PDF: 129.43 Kb.

RESUMEN

La enfermedad de Kawasaki es una vasculitis sistémica de probable etiología infecciosa con una serie de respuestas inmunológicas en cascada, que producen un cuadro clínico caracterizado por fiebre elevada persistente de más de 5 días de evolución que no responde al manejo médico antipirético o antimicrobiano, y que se acompaña de por lo menos 4 de los siguientes criterios: conjuntivitis no exudativa, adenopatía cervical no supurada, cambios inflamatorios bucales con severo enrojecimiento y congestión de labios, lengua y orofaringe; erupción eritematosa morbiliforme con importante edema e inflamación en porción distal de las extremidades que posteriormente presenta descamación de la piel a nivel de los dedos. Este trabajo es una revisión de las bases inmunológicas actuales que resume los recientes resultados de las investigaciones reportadas en la literatura médica mundial; su objetivo es proporcionar un panorama de actualidad sobre los nuevos conocimientos que permiten una mejor comprensión en la respuesta inmunológica de la enfermedad de Kawasaki.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment and proposal for future research. Arch Dis Child 2002; 86: 286-90.

2. Meissner HC, Leung DY. Kawasaki syndrome: where are the answers? Pediatrics 2003; 112: 672-5.

3. Meissner HC, Leung DY. Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr Infect Dis J 2000; 19: 91-4.

4. Suzuki H, Noda E, Miyawaki M, Takeuchi T, Uemura S, Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatr Int 2001; 43: 115-9.

5. Sohn MH, Noh SY, Chang W, Shin KM, Kim DS. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol. 2003; 32: 364-6.

6. Chua PK, Malish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 2003; 10: 308-14.

7. Jang GC, Kim HY, Ahn SY, Kim DS. Raised serum interleukin 15 levels in Kawasaki disease. Ann Rheum Dis 2003; 62: 264-6.

8. Shikishima Y, Saeki T, Matsuura N. Chemokines in Kawasaki disease: measurement of CCL2, CCL22 and CXCL10. Asian Pac J Allergy Immunol 2003; 21: 139-43.

9. Terai M, Yasukawa K, Honda T, Jibiki T, Hirano K, Sato J, Ishiwada N, Seguchi M, Ueda S, Kohno Y. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002; 21: 777-81.

10. Suzuki H, Muragaki Y, Uemura S, Takeuchi T, Minami T, Shibura S, Ohshima A, Yoshikawa N. Detection of auto-antibodies against a 70 kDa protein derived from vascular smooth muscle cells in patients with Kawasaki disease. Eur J Pediatr 2002; 161: 324-9.

11. Biezeveld MH, Kuipers IM, Geissler J, Lam J, Ottenkamp JJ, Hack CE, Kuijpers TW. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 2003; 361: 1268-70.

12. Furui J, Ishii M, Ikeda H, Muta H, Egami K, Sugahara Y, Himeno W, Akagi T, Kato H, Matsuishi T. Soluble forms of the selectin family in children with Kawasaki disease: prediction for coronary artery lesions. Acta Paediatr 2002; 91: 1183-8.

13. Takeshita S, Kawase H, Shimizu T, Yoshida M, Sekine I. Increased production of serum IgA-class antibody to lipid A in Kawasaki disease. Pediatr Int 2002; 44: 5-11.

14. Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001; 166: 1334-43.

15. Gupta J, Johann-Liang R, Bussel JB, Gersony WM, Lehman TJ. Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease. Cardiology 2002; 97: 180-2.

16. Khajoee V, Kariyazono H, Ohno T, Ihara K, Mizuno Y, Kusuhara K, Hara T. Inducible and endothelial constitutive nitric oxide synthase gene polymorphisms in Kawasaki disease. Pediatr Int 2003; 45: 130-4.

17. Yu X, Hirono KI, Ichida F, Uese KI, Rui C, Watanabe S, Watanabe K, Hashimoto I, Kumada T, Okada E, Terai M, Suzuki A, Miyawaki T. Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesions in acute Kawasaki disease. Pediatr Res 2004; 55: 688-94.

18. Samada K, Igarashi H, Shiraishi H, Hatake K, Momoi MY. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease. Eur J Pediatr 2002; 161: 538-41.

19. Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, Yang KD. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003; 111: 140-7.

20. Chua PK, Yanagihara R, Melish ME, Nerurkar VR. Modulation of adhesion molecules and monocyte chemoattractant protein by tumor necrosis factor-alpha and salicylic acid in primary human coronary artery endothelial cells. Cell Mol Biol 2003; 49: 1157-66.

21. Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21: 193-9.

22. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004; 144: 496-9.

23. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-10.